名媛直播

Amid controversy and discussions about the high cost of cancer drugs, some academic medical centers profit handsomely from pharma-paid . (Los Angeles Magazine)

The FDA has mandated updates to related to a serious risk of T-cell malignancies associated with all BCMA- and CD-19 targeted therapies, saying that patients "should be monitored life-long for secondary malignancies."

The Air Force is looking into findings from a recent study that showed higher rates of a among children of personnel at Cannon Air Force Base in New Mexico. (Military.com)

-- injectable radioactive drugs -- is the "new target" in pharma's race to develop, and acquire, cancer therapies. (Bloomberg)

A 40-year smoker heeded the call to get , and it saved her life. (NPR)

Roche announced that adding glofitamab (Columvi) to chemotherapy significantly improved overall survival (OS) in versus chemotherapy alone.

AstraZeneca announced that adding durvalumab (Imfinzi) to chemotherapy improved 3-year OS in as compared with chemotherapy alone.

Some patients aren't waiting for approval of . (Washington Post)

Newly discovered could provide impetus for new approaches to treatment. (UCLA)

By studying ovarian cancer specimens, researchers found cellular patterns that may help identify patients who are likely to . (Cedars-Sinai)

Extracting dormant immune cells from a tumor and then activating and infusing them back into the tumor offers a promising approach to treat . (University of Pittsburgh Medical Center, Nature Communications)

With help from artificial intelligence, researchers found they could double the . (Science Translational Medicine)

Comment